Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application

 
• By Sarah Karlin-Smith

As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.

Syringe vaccine and vaccine production. Mass-produced syringes with the vaccine contained in it. The new syringes are labelled with the word “vaccine” and the needles have a grey safety lid on them.
Novavax CEO Stanley Erck discussed his company's vaccine portfolio 10 September

More from Vaccines

More from Pink Sheet